Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARL002
- Development stage
- Preclinical
- Lead developer
- Korea Arlico Pharm
- Modality
- Small Molecules
01
Overview
ARL002 is an investigational new drug (NCE) being developed by Korea Arlico Pharm for the treatment of central nervous system (CNS) disorders. As a new drug (신약) in the company's pipeline, it represents a novel chemical entity rather than a generic or modified formulation. While the specific molecular target and mechanism of action have not been publicly disclosed, the development of ARL002 is part of Korea Arlico Pharm's strategic focus on expanding its portfolio in the CNS therapeutic area, which includes research into neurodegenerative conditions such as Alzheimer's and Parkinson's diseases.
- Other names
- ARL002ARL-002ARL 002
Beyond the preview
Go deeper on ARL002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARL002.